RxDoctor Payments Data

William Hogancamp, MD

Neurology · Paducah, KYNPI 1164432613

Payments from drug & device makers

$7,833in general payments, 2019–2025

Across 552 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$563
  • Supernus Pharmaceuticals, Inc.$537
  • AstraZeneca$321
  • Bristol Myers Squibb$297
  • Biogen$266
  • plus $4K from 42 others

What the payments were for

  • Speaking & faculty fees$721%
  • Food & beverage$7,39994%
  • Education$3615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,833 in reported general payments places this provider in the 60th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$106,855
Medicare patients
653
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide17$177,341
CopaxoneGlatiramer Acetate30$175,001
FingolimodFingolimod Hcl42$171,470
GilenyaFingolimod Hcl14$144,988
Sodium Oxybate11$127,378
NuplazidPimavanserin Tartrate11$55,714
Emgality PenGalcanezumab-Gnlm74$52,182
Nurtec OdtRimegepant Sulfate29$42,778
EliquisApixaban40$24,792
Dalfampridine ErDalfampridine15$18,835
NamzaricMemantine Hcl/Donepezil Hcl18$16,247
Carbidopa-Levodopa ErCarbidopa/Levodopa99$8,611
Dimethyl Fumarate35$7,219
Modafinil65$7,126
OxycontinOxycodone Hcl12$7,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$96$177,34117 claims
Teva Pharmaceuticals USA, Inc.Copaxone$264$175,00130 claims
NovartisGilenya$258$144,98814 claims
PfizerNurtec Odt, Eliquis$563$67,57069 claims
Acadia Pharmaceuticals IncNuplazid$228$55,71411 claims
AbbVieNamzaric$2,235$16,24718 claims
AstraZenecaBrilinta$321$5,76313 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$11$1,91534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 210 neurology providers in Kentucky.

Other neurology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →